Idenix Pharmaceuticals, Inc. - Common Stock

Estee Lauder Companies, Inc.'s (NYSE:EL) second quarter 2012 quarterly earnings increased 17% year over year to $1.00 per share, but missed the Zacks Consensus Estimate of $1.01 by a penny After concerns arose that Idenix Pharmaceuticals, ...

• Estee Lauder Companies, Inc.'s (NYSE:EL) second quarter 2012 quarterly earnings increased 17% year over year to $1.00 per share, but missed the Zacks Consensus Estimate of $1.01 by a penny • After concerns arose that Idenix Pharmaceuticals, ...

(RTTNews.com) - The biotechnology sector, though a risky investment arena, offers a tremendous potential for huge gains. Binary events like clinical trial results and FDA decisions are typical in biotechnology companies, and can cause significant ...

At market close on Friday, the Dow Jones Industrial Average was up 1.2%, the NASDAQ up 1.4%, and the S&P 500 up 1.4%. Boston saw its best-known stocks finish up with the market, closing up 2.4%.

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the US Food and Drug ...